Head and Neck Cancer

ClinicalJuly 5, 2026

Neoadjuvant Therapy Trial for Head and Neck Squamous Cell Carcinoma Initiated

A clinical trial is evaluating the safety and tolerability of a combination of immune-targeted therapy and lysogenic HSV-based virotherapy in patients with resectable head and neck squamous cell carcinoma.

Companies

Assets

Recent signals(5)

Neoadjuvant Therapy Trial for Head and Neck Squamous Cell Carcinoma Initiated

Durvalumab and Cetuximab Combination Trial for Head and Neck Cancer

Phase 2 Trial of SX-682 and Docetaxel in Advanced Head and Neck and Prostate Cancers

Phase II/III Trial Compares Weekly vs. Every Three Weeks Cisplatin in Advanced Head and Neck Cancer

Phase II Trial of Axelopran with Pembrolizumab in Head and Neck Cancer

Upcoming catalysts

Indications

Get signals before the market moves